• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prostate cancer: No evidence for adjuvant chemotherapy in high-risk disease.

作者信息

Albers Peter

机构信息

Department of Urology, University Hospital Duesseldorf, Moorenstrasse 5, D-40225 Duesseldorf, Germany.

出版信息

Nat Rev Urol. 2015 Nov;12(11):602-3. doi: 10.1038/nrurol.2015.219. Epub 2015 Sep 1.

DOI:10.1038/nrurol.2015.219
PMID:26334083
Abstract
摘要

相似文献

1
Prostate cancer: No evidence for adjuvant chemotherapy in high-risk disease.前列腺癌：高危疾病中辅助化疗无证据支持。
Nat Rev Urol. 2015 Nov;12(11):602-3. doi: 10.1038/nrurol.2015.219. Epub 2015 Sep 1.
2
Role for androgen withdrawal prior to radiation and surgery for prostate cancer?
Oncology (Williston Park). 1997 May;11(5):738.
3
[Diagnosis and treatment of early prostate cancer].
Vopr Onkol. 2009;55(3):382-5.
4
Role of radiation and androgen deprivation therapy for advanced prostate cancer.放疗和雄激素剥夺疗法在晚期前列腺癌治疗中的作用。
Curr Probl Cancer. 2015 Jan-Feb;39(1):41-7. doi: 10.1016/j.currproblcancer.2014.11.007. Epub 2014 Nov 25.
5
Ageism in the undertreatment of high-risk prostate cancer: how long will clinical practice patterns resist the weight of evidence?高危前列腺癌治疗不足中的年龄歧视：临床实践模式对证据的压力还能抵抗多久？
J Clin Oncol. 2015 Mar 1;33(7):676-8. doi: 10.1200/JCO.2014.59.4093. Epub 2015 Jan 5.
6
Androgen suppression plus radiation for prostate cancer.雄激素抑制联合放疗治疗前列腺癌。
JAMA. 2004 Dec 1;292(21):2581-2; author reply 2582. doi: 10.1001/jama.292.21.2581-b.
7
Adjuvant medical therapy for prostate cancer.前列腺癌的辅助医学治疗。
Expert Opin Pharmacother. 2011 Jan;12(1):73-84. doi: 10.1517/14656566.2010.516252. Epub 2010 Dec 1.
8
Treatment of prostate cancer with hormonal therapy in Europe.
BJU Int. 2009 Mar;103 Suppl 2:2-6. doi: 10.1111/j.1464-410X.2009.08382.x.
9
Radiation therapy and androgen suppression as treatment for clinically localized prostate cancer: the new standard?放射治疗和雄激素抑制作为临床局限性前列腺癌的治疗方法：新的标准？
JAMA. 2004 Aug 18;292(7):864-6. doi: 10.1001/jama.292.7.864.
10
Carcinoma of the prostate: neoadjuvant hormonotherapy followed by radiotherapy.前列腺癌：新辅助激素治疗后放疗。
Acta Urol Belg. 1996 May;64(2):63-4.

本文引用的文献

1
A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902.一项针对高危前列腺癌进行两年雄激素抑制联合放疗并联合或不联合辅助化疗的3期试验：放射治疗肿瘤学组3期随机试验NRG肿瘤学RTOG 9902的最终结果
Int J Radiat Oncol Biol Phys. 2015 Oct 1;93(2):294-302. doi: 10.1016/j.ijrobp.2015.05.024. Epub 2015 Jul 21.
2
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911).根治性前列腺切除术后高危前列腺癌的术后放疗：一项随机对照试验（EORTC 试验 22911）的长期结果。
Lancet. 2012 Dec 8;380(9858):2018-27. doi: 10.1016/S0140-6736(12)61253-7. Epub 2012 Oct 19.
3
Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02.一项针对高危前列腺癌的Ⅲ期多机构试验：比较紫杉醇、雌莫司汀和口服依托泊苷联合长期雄激素抑制疗法及放疗的辅助化疗与单纯长期雄激素抑制加放疗的疗效——RTOG 99-02的初步毒性分析
Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):672-8. doi: 10.1016/j.ijrobp.2008.05.020. Epub 2008 Nov 5.
4
Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31.雄激素抑制联合放疗与单纯放疗用于D1期/病理淋巴结阳性前列腺腺癌患者：基于放射治疗肿瘤学组85-31全国前瞻性随机试验的更新结果
J Clin Oncol. 2005 Feb 1;23(4):800-7. doi: 10.1200/JCO.2005.08.141.
5
Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.在前列腺特异性抗原时代接受治疗的临床局限性前列腺癌患者手术后或放疗后的癌症特异性死亡率。
J Clin Oncol. 2003 Jun 1;21(11):2163-72. doi: 10.1200/JCO.2003.01.075.
6
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.局部晚期前列腺癌患者立即进行雄激素抑制和外照射的长期结果（一项欧洲癌症研究与治疗组织的研究）：一项III期随机试验
Lancet. 2002 Jul 13;360(9327):103-6. doi: 10.1016/s0140-6736(02)09408-4.
7
Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer.对诊断时年龄在55至74岁、采用保守治疗的临床局限性前列腺癌男性患者进行竞争风险分析。
JAMA. 1998 Sep 16;280(11):975-80. doi: 10.1001/jama.280.11.975.
8
Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?是否有证据表明化疗对前列腺癌患者有益？
J Clin Oncol. 1985 Jul;3(7):1013-21. doi: 10.1200/JCO.1985.3.7.1013.